비인두암종(NPC)이라는 유형의 암을 치료하기 위해 화학요법 약물과 병용하여 신약인 Nivolumab을 사용한 연구
새로 진단된 비인두암종(NPC)에서 젬시타빈, 시스플라틴 및 니볼루맙을 이용한 화학면역요법을 사용한 2상 연구
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
연구 개요
상태
개입 / 치료
- 다른: Quality-of-Life Assessment
- 의약품: Cisplatin
- 절차: Biospecimen Collection
- 절차: Computed Tomography
- 절차: Magnetic Resonance Imaging
- 다른: Questionnaire Administration
- 절차: Echocardiography Test
- 절차: Multigated Acquisition Scan
- 절차: Positron Emission Tomography
- 생물학적: Nivolumab
- 의약품: Gemcitabine
- 절차: Biopsy Procedure
- 절차: Chest Radiography
- 다른: Electronic Health Record Review
- 방사능: Radiation Therapy
- 다른: Fluciclovine F18
- 절차: X-Ray Imaging
상세 설명
PRIMARY OBJECTIVE:
I. To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher immune related adverse events (irAEs).
SECONDARY OBJECTIVES:
I. To estimate the 2-year event-free survival (EFS) of children, adolescents and young adults with NPC who are treated with induction chemoimmunotherapy (CIT), followed by consolidation chemoradioimmunotherapy (CRIT, cisplatin, nivolumab and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy.
II. To evaluate the objective response rate (ORR) including complete responders and partial responders (complete response [CR] + partial response [PR]) of neoadjuvant CIT.
III. To evaluate feasibility of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC).
IV. To evaluate the cumulative incidence of local and distant relapse.
EXPLORATORY OBJECTIVES:
I. To estimate 5-year EFS and overall survival (OS) of children with NPC who are treated with induction CIT followed by consolidation CRIT, and nivolumab maintenance therapy.
II. To compare response assessed by fludeoxyglucose F18 (FDG) positron emission tomography (PET) versus magnetic resonance imaging (MRI).
III. To determine treatment outcomes for patients treated with radiation per protocol versus (vs) deviation.
IV. To evaluate outcomes comparing patients receiving intensity modulated radiation therapy (IMRT) to proton therapy.
V. To objectively measure both acute and long-term toxicity including immune related adverse events and radiation late effects.
VI. To evaluate swallowing dysfunction using patient reported outcome (PRO) measures for children and adults throughout the protocol for up to 5 years.
VII. To evaluate quality of life (QOL) using Patient-Reported Outcomes Measurement Information System (PROMIS) multidimensional questionnaire throughout the protocol for up to 5 years.
VIII. To correlate the lymphocyte to monocyte ratio on complete blood counts (CBCs) with treatment response and outcomes.
IX. To collect and bank specimens (including tumor and blood) for future research studies.
X. To compare dental x-rays in patients prior to radiation and 1 year post radiation to evaluate for dental caries and bone health.
OUTLINE:
INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, gemcitabine IV over 30 minutes on days 1 and 8 of each cycle, and cisplatin IV over 3-6 hours on day 1 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cisplatin IV over 3-6 hours on day 1 of cycles 1-2. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive concurrent radiation therapy on trial.
MAINTENANCE THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on trial. Patients undergo MRI, FDG PET, and computed tomography (CT) throughout the trial and chest x-ray during follow-up. Patients also undergo dental x-ray imaging on the trial. Patients may optionally undergo tissue biopsy and blood sample collection during screening and on trial.
After completion of study treatment, patients are followed up every 3 months for 12 months, every 6 months until 24 months off therapy, and then yearly until 5 years off therapy.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Christchurch, 뉴질랜드, 8011
- 모병
- Christchurch Hospital
-
수석 연구원:
- Tristan Pettit
-
연락하다:
- Site Public Contact
- 전화번호: 03 364 0640
-
-
Auckland
-
Grafton, Auckland, 뉴질랜드, 1145
- 모병
- Starship Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 0800 728 436
-
수석 연구원:
- Leander D. Timothy
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- 모병
- Children's Hospital of Alabama
-
연락하다:
- Site Public Contact
- 전화번호: 205-638-9285
- 이메일: oncologyresearch@peds.uab.edu
-
수석 연구원:
- Jamie M. Aye
-
-
Arizona
-
Phoenix, Arizona, 미국, 85016
- 모병
- Phoenix Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 602-546-0920
-
수석 연구원:
- Alok K. Kothari
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72202-3591
- 모병
- Arkansas Children's Hospital
-
수석 연구원:
- Michael W. Bishop
-
연락하다:
- Site Public Contact
- 전화번호: 501-364-7373
-
-
California
-
Downey, California, 미국, 90242
- 모병
- Kaiser Permanente Downey Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 626-564-3455
-
수석 연구원:
- Robert M. Cooper
-
Loma Linda, California, 미국, 92354
- 모병
- Loma Linda University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 909-558-4050
-
수석 연구원:
- Albert Kheradpour
-
Los Angeles, California, 미국, 90027
- 모병
- Children's Hospital Los Angeles
-
수석 연구원:
- Rachana Shah
-
연락하다:
- Site Public Contact
- 전화번호: 323-361-4110
-
Madera, California, 미국, 93636
- 모병
- Valley Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 559-353-3000
- 이메일: Research@valleychildrens.org
-
수석 연구원:
- Ruetima Titapiwatanakun
-
Oakland, California, 미국, 94611
- 모병
- Kaiser Permanente-Oakland
-
연락하다:
- Site Public Contact
- 전화번호: 877-642-4691
- 이메일: Kpoct@kp.org
-
수석 연구원:
- Aarati V. Rao
-
Oakland, California, 미국, 94609
- 모병
- UCSF Benioff Children's Hospital Oakland
-
수석 연구원:
- Jennifer G. Michlitsch
-
연락하다:
- Site Public Contact
- 전화번호: 510-428-3264
- 이메일: PedOncRschOAK@ucsf.edu
-
San Diego, California, 미국, 92123
- 모병
- Rady Children's Hospital - San Diego
-
연락하다:
- Site Public Contact
- 전화번호: 858-966-5934
-
수석 연구원:
- William D. Roberts
-
San Francisco, California, 미국, 94158
- 모병
- UCSF Medical Center-Mission Bay
-
연락하다:
- Site Public Contact
- 전화번호: 877-827-3222
- 이메일: cancertrials@ucsf.edu
-
수석 연구원:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado
-
수석 연구원:
- Navin R. Pinto
-
연락하다:
- Site Public Contact
- 전화번호: 303-764-5056
- 이메일: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- 모병
- Connecticut Children's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 860-545-9981
-
수석 연구원:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, 미국, 19803
- 모병
- Alfred I duPont Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- Children's National Medical Center
-
수석 연구원:
- Jeffrey S. Dome
-
연락하다:
- Site Public Contact
- 전화번호: 202-476-2800
- 이메일: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville, Florida, 미국, 32610
- 모병
- UF Health Cancer Institute - Gainesville
-
연락하다:
- Site Public Contact
- 전화번호: 352-273-8010
- 이메일: cancer-center@ufl.edu
-
수석 연구원:
- Brian Stover
-
Jacksonville, Florida, 미국, 32207
- 모병
- Nemours Children's Clinic-Jacksonville
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Sridhi Patel
-
Miami, Florida, 미국, 33155
- 모병
- Nicklaus Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 888-624-2778
-
수석 연구원:
- Ziad A. Khatib
-
Orlando, Florida, 미국, 32806
- 모병
- Arnold Palmer Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 321-841-5357
- 이메일: Jennifer.spinelli@orlandohealth.com
-
수석 연구원:
- Zhongbo Hu
-
Orlando, Florida, 미국, 32827
- 모병
- Nemours Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Sridhi Patel
-
Pensacola, Florida, 미국, 32504
- 모병
- Nemours Children's Clinic - Pensacola
-
연락하다:
- Site Public Contact
- 이메일: helpdesk@childrensoncologygroup.org
-
수석 연구원:
- Jeffrey H. Schwartz
-
Tampa, Florida, 미국, 33607
- 모병
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
연락하다:
- Site Public Contact
- 전화번호: 813-357-0849
- 이메일: jennifer.manns@baycare.org
-
수석 연구원:
- Don E. Eslin
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 모병
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
수석 연구원:
- Sarah G. Mitchell
-
연락하다:
- Site Public Contact
- 전화번호: 404-785-0232
- 이메일: Olivia.Floyd@choa.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Lurie Children's Hospital-Chicago
-
수석 연구원:
- Amy L. Walz
-
연락하다:
- Site Public Contact
- 전화번호: 773-880-4562
-
Chicago, Illinois, 미국, 60637
- 정지된
- University of Chicago Comprehensive Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Riley Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 800-248-1199
-
수석 연구원:
- Marissa Just
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 아직 모집하지 않음
- University of Kentucky/Markey Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 859-257-3379
-
수석 연구원:
- James T. Badgett
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70118
- 모병
- Children's Hospital New Orleans
-
수석 연구원:
- Maria C. Velez-Yanguas
-
연락하다:
- Site Public Contact
- 전화번호: 504-894-5377
-
-
Maine
-
Scarborough, Maine, 미국, 04074
- 모병
- Maine Children's Cancer Program
-
수석 연구원:
- Aaron R. Weiss
-
연락하다:
- Site Public Contact
- 전화번호: 207-396-8670
- 이메일: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 410-955-8804
- 이메일: jhcccro@jhmi.edu
-
수석 연구원:
- Robyn D. Gartrell
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana-Farber Cancer Institute
-
수석 연구원:
- Allison F. O'Neill
-
연락하다:
- Site Public Contact
- 전화번호: 877-442-3324
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49503
- 모병
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 616-391-1230
- 이메일: crcwm-regulatory@crcwm.org
-
수석 연구원:
- Kathleen Y. Butler
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic in Rochester
-
연락하다:
- Site Public Contact
- 전화번호: 855-776-0015
-
수석 연구원:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- 모병
- University of Mississippi Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 601-815-6700
-
수석 연구원:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, 미국, 64108
- 모병
- Children's Mercy Hospitals and Clinics
-
수석 연구원:
- Keith J. August
-
연락하다:
- Site Public Contact
- 전화번호: 816-302-6808
- 이메일: COGResearchGroup@cmh.edu
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School of Medicine
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Frederick S. Huang
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68114
- 모병
- Children's Hospital and Medical Center of Omaha
-
연락하다:
- Site Public Contact
- 전화번호: 402-955-3949
-
수석 연구원:
- Jill C. Beck
-
Omaha, Nebraska, 미국, 68198
- 모병
- University of Nebraska Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 402-559-6941
- 이메일: unmcrsa@unmc.edu
-
수석 연구원:
- Jill C. Beck
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- 모병
- Hackensack University Medical Center
-
수석 연구원:
- Katharine Offer
-
연락하다:
- Site Public Contact
- 전화번호: 551-996-2897
-
Neptune City, New Jersey, 미국, 07753
- 모병
- Jersey Shore Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 732-776-4240
-
수석 연구원:
- Katharine Offer
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
수석 연구원:
- Scott Moerdler
-
연락하다:
- Site Public Contact
- 전화번호: 732-235-8675
-
Newark, New Jersey, 미국, 07112
- 모병
- Newark Beth Israel Medical Center
-
수석 연구원:
- Scott Moerdler
-
연락하다:
- Site Public Contact
- 전화번호: 973-926-7230
- 이메일: Christine.Kosmides@rwjbh.org
-
수석 연구원:
- Teena Bhatla
-
-
New York
-
Albany, New York, 미국, 12208
- 모병
- Albany Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 518-262-5513
-
수석 연구원:
- Lauren R. Weintraub
-
The Bronx, New York, 미국, 10467
- 모병
- Montefiore Medical Center - Moses Campus
-
연락하다:
- Site Public Contact
- 전화번호: 718-379-6866
- 이메일: eskwak@montefiore.org
-
수석 연구원:
- Alice Lee
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28203
- 모병
- Carolinas Medical Center/Levine Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 800-804-9376
-
수석 연구원:
- Joel A. Kaplan
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center
-
수석 연구원:
- Jessica M. Sun
-
연락하다:
- Site Public Contact
- 전화번호: 888-275-3853
-
Greenville, North Carolina, 미국, 27834
- 모병
- East Carolina University
-
연락하다:
- Site Public Contact
- 전화번호: 252-744-1015
- 이메일: eubankss@ecu.edu
-
수석 연구원:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Wake Forest University Health Sciences
-
연락하다:
- Site Public Contact
- 전화번호: 336-713-6771
-
수석 연구원:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58122
- 모병
- Sanford Broadway Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 701-323-5760
- 이메일: OncologyClinicalTrialsFargo@sanfordhealth.org
-
수석 연구원:
- Samuel J. Milanovich
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 513-636-2799
- 이메일: cancer@cchmc.org
-
수석 연구원:
- Brian K. Turpin
-
Cleveland, Ohio, 미국, 44106
- 모병
- Rainbow Babies and Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 216-844-5437
-
수석 연구원:
- Duncan S. Stearns
-
Columbus, Ohio, 미국, 43205
- 모병
- Nationwide Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 614-722-6039
- 이메일: Melinda.Triplet@nationwidechildrens.org
-
수석 연구원:
- Mark A. Ranalli
-
Dayton, Ohio, 미국, 45404
- 모병
- Dayton Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-228-4055
-
수석 연구원:
- Jordan M. Wright
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- University of Oklahoma Health Sciences Center
-
연락하다:
- Site Public Contact
- 전화번호: 405-271-8777
- 이메일: ou-clinical-trials@ouhsc.edu
-
수석 연구원:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18103
- 모병
- Lehigh Valley Hospital-Cedar Crest
-
연락하다:
- Site Public Contact
- 전화번호: 610-402-9543
- 이메일: Morgan_M.Horton@lvhn.org
-
수석 연구원:
- Jacob A. Troutman
-
Hershey, Pennsylvania, 미국, 17033
- 모병
- Penn State Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 717-531-6012
-
수석 연구원:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
연락하다:
- Site Public Contact
- 전화번호: 267-425-5544
- 이메일: CancerTrials@email.chop.edu
-
수석 연구원:
- Theodore W. Laetsch
-
Pittsburgh, Pennsylvania, 미국, 15224
- 모병
- Children's Hospital of Pittsburgh of UPMC
-
연락하다:
- Site Public Contact
- 전화번호: 412-692-8570
- 이메일: jean.tersak@chp.edu
-
수석 연구원:
- Brittani K. Seynnaeve
-
-
South Carolina
-
Columbia, South Carolina, 미국, 29203
- 모병
- Prisma Health Richland Hospital
-
수석 연구원:
- Stuart L. Cramer
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, 미국, 29605
- 모병
- BI-LO Charities Children's Cancer Center
-
수석 연구원:
- Aniket Saha
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57117-5134
- 모병
- Sanford USD Medical Center - Sioux Falls
-
연락하다:
- Site Public Contact
- 전화번호: 605-312-3320
- 이메일: OncologyClinicalTrialsSF@SanfordHealth.org
-
수석 연구원:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38105
- 모병
- Saint Jude Children's Research Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 888-226-4343
- 이메일: referralinfo@stjude.org
-
수석 연구원:
- Catherine G. Lam
-
Nashville, Tennessee, 미국, 37232
- 모병
- Vanderbilt University/Ingram Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-811-8480
-
수석 연구원:
- Scott C. Borinstein
-
Nashville, Tennessee, 미국, 37203
- 모병
- The Children's Hospital at TriStar Centennial
-
연락하다:
- Site Public Contact
- 전화번호: 615-342-1919
-
수석 연구원:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, 미국, 78723
- 모병
- Dell Children's Medical Center of Central Texas
-
연락하다:
- Site Public Contact
- 전화번호: 512-628-1902
- 이메일: TXAUS-DL-SFCHemonc.research@ascension.org
-
수석 연구원:
- Shannon M. Cohn
-
Dallas, Texas, 미국, 75390
- 모병
- UT Southwestern/Simmons Cancer Center-Dallas
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@UTSouthwestern.edu
-
수석 연구원:
- Avanthi T. Shah
-
Fort Worth, Texas, 미국, 76104
- 모병
- Cook Children's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 682-885-2103
- 이메일: CookChildrensResearch@cookchildrens.org
-
수석 연구원:
- Chelsee Greer
-
Houston, Texas, 미국, 77030
- 모병
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 713-798-1354
- 이메일: burton@bcm.edu
-
수석 연구원:
- Mehmet F. Okcu
-
Houston, Texas, 미국, 77030
- 모병
- UT MD Anderson Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 866-632-6789
- 이메일: askmdanderson@mdanderson.org
-
수석 연구원:
- Najat C. Daw
-
San Antonio, Texas, 미국, 78207
- 모병
- Children's Hospital of San Antonio
-
연락하다:
- Site Public Contact
- 전화번호: 210-704-2894
- 이메일: bridget.medina@christushealth.org
-
수석 연구원:
- Julie Voeller
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- 모병
- University of Virginia Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 434-243-6303
- 이메일: uvacancertrials@hscmail.mcc.virginia.edu
-
수석 연구원:
- Brian C. Belyea
-
Norfolk, Virginia, 미국, 23507
- 모병
- Children's Hospital of The King's Daughters
-
연락하다:
- Site Public Contact
- 전화번호: 757-668-7243
- 이메일: CCBDCresearch@chkd.org
-
수석 연구원:
- Melissa S. Mark
-
Richmond, Virginia, 미국, 23298
- 모병
- VCU Massey Comprehensive Cancer Center
-
수석 연구원:
- Madhu S. Gowda
-
연락하다:
- Site Public Contact
- 전화번호: 804-628-6430
- 이메일: CTOclinops@vcu.edu
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 866-987-2000
-
수석 연구원:
- Sarah E. Leary
-
Tacoma, Washington, 미국, 98405
- 모병
- Mary Bridge Children's Hospital and Health Center
-
연락하다:
- Site Public Contact
- 전화번호: 253-403-1461
- 이메일: research@multicare.org
-
수석 연구원:
- Robert G. Irwin
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- Children's Hospital of Wisconsin
-
수석 연구원:
- Angela Steineck
-
연락하다:
- Site Public Contact
- 전화번호: 414-955-4727
- 이메일: MACCCTO@mcw.edu
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T3B 6A8
- 모병
- Alberta Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 403-220-6898
- 이메일: research4kids@ucalgary.ca
-
수석 연구원:
- Victor A. Lewis
-
Edmonton, Alberta, 캐나다, T6G 2B7
- 모병
- University of Alberta Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 780-407-8798
- 이메일: pedsoncologyresearch@ahs.ca
-
수석 연구원:
- Sarah J. McKillop
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 1X8
- 모병
- Hospital for Sick Children
-
연락하다:
- Site Public Contact
- 전화번호: 416-813-7654
- 이메일: ask.CRS@sickkids.ca
-
수석 연구원:
- Avram E. Denburg
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3H 1P3
- 모병
- The Montreal Children's Hospital of the MUHC
-
연락하다:
- Site Public Contact
- 전화번호: 514-412-4445
- 이메일: info@thechildren.com
-
수석 연구원:
- Stephanie Mourad
-
Montreal, Quebec, 캐나다, H3T 1C5
- 모병
- Centre Hospitalier Universitaire Sainte-Justine
-
수석 연구원:
- Monia Marzouki
-
연락하다:
- Site Public Contact
- 전화번호: 514-345-4931
- 이메일: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, 캐나다, J1H 5N4
- 모병
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
연락하다:
- Site Public Contact
- 전화번호: 819-820-6480
- 이메일: crcinformation.chus@ssss.gouv.qc.ca
-
수석 연구원:
- Stephanie Vairy
-
-
-
-
-
San Juan, 푸에르토 리코, 00926
- 모병
- University Pediatric Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 787-474-0333
-
수석 연구원:
- Maria E. Echevarria
-
-
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, 호주, 2310
- 모병
- John Hunter Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: (02) 4985 5180
-
수석 연구원:
- Kristy McCarthy
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patients must be ≤ 21 years of age at the time of study enrollment
-
Newly diagnosed American Joint Committee on Cancer (AJCC) (8th edition) stage II-IV nasopharyngeal carcinoma (NPC)
- Patients must have had histologic verification of the malignancy at original diagnosis
- Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have had histologic verification of the malignancy at original diagnosis
-
Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60%
-
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy)
-
Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy)
-
A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL)
1 month to < 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to < 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female)
- to < 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female)
- to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
6 to < 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to <13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female) â ¥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy)
-
Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (within 7 days prior to start of protocol therapy)
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
Shortening fraction of ≥ 27% by echocardiogram, or
-
Ejection fraction of ≥ 50% by radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
-
Patients who received prior radiotherapy to the head or neck
-
Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission
-
Patients with a diagnosis of immunodeficiency
-
Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded
-
Patients with a condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease
-
Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis
-
Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time
-
Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer
-
Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Treatment (nivolumab, gemcitabine, cisplatin, radiation)
See Detailed Description |
Ancillary studies
다른 이름들:
Given IV
다른 이름들:
Undergo blood sample collection
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Ancillary studies Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Undergo PET
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo tissue biopsy
다른 이름들:
Undergo chest x-ray
다른 이름들:
Ancillary studies Receive radiation therapy
다른 이름들:
Given IV
다른 이름들:
Undergo dental x-ray
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of grade 3 or higher immune-related adverse events (irAE) during induction chemoimmunotherapy (CIT)
기간: Until the end of consolidation therapy
|
Will be assessed by Common Terminology Criteria for Adverse Events (8th edition). IrAEs include diarrhea (noninfectious), colitis (noninfectious), pneumonitis (noninfectious), myocarditis, elevated alanine aminotransferase, elevated aspartate aminotransferase, pancreatitis, elevated blood bilirubin, hypophysitis and hyperthyroid considered possibly, probably, or definitely related to nivolumab. |
Until the end of consolidation therapy
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Event-free survival (EFS)
기간: From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
EFS along with the 95% confidence intervals will be estimated using the Kaplan-Meier method. The EFS will be reported separately for patients with non-metastatic disease and those with metastatic disease (if there are enough patients with metastatic disease enrolled). |
From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
|
Objective response rate
기간: At the end of induction CIT
|
Will be defined as the rate of responders among evaluable patients using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
At the end of induction CIT
|
|
Feasibility success of the induction regimen
기간: At the end of induction CIT
|
Will be defined as the completion of three cycles of induction without delay of greater than 30 days for radiation initiation due to toxicity in 80% of patients. |
At the end of induction CIT
|
|
Cumulative incidence of local or distant relapse
기간: Up to 5 years
|
Defined as a function of time since enrollment will be estimated by the method of Gray. |
Up to 5 years
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EFS
기간: At 5 years
|
Will be assessed using Kaplan-Meier estimates. |
At 5 years
|
|
Overall survival
기간: From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
Will be assessed using Kaplan-Meier estimates. |
From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
|
Proportion of patients who achieve complete response
기간: At the end of induction and maintenance
|
Will be assessed by retrospective central review by the proportion of patients who achieve complete response by magnetic resonance imaging using RECIST 1.1 criteria and the proportion of patients who achieve complete metabolic response using Positron Emission Tomography Response Criteria In Solid Tumors criteria at the end of induction and the end of maintenance based on central review will be presented. A two-way table of response assessments according to the two modalities will be constructed and McNemar's test will be performed to evaluate the concordance. |
At the end of induction and maintenance
|
|
Protocol deviation related to radiation therapy delivery
기간: Up to 5 years
|
Will be assessed by retrospective central review. The effect of deviation, categorized as present or absent by the central reviewer, on the hazard of EFS will be estimated by Cox proportional hazard model. The hazard ratio will be reported along with 95% confidence interval. |
Up to 5 years
|
|
EFS in patients receiving intensity modulated radiation therapy with those who receive proton therapy
기간: Up to 5 years
|
Will be assessed using a log-rank test. |
Up to 5 years
|
|
Incidence of grade 3 or higher adverse events
기간: Up to 5 years
|
Will be assessed during protocol therapy. The incidence of these events will be reported for each toxicity term. Furthermore, the irAE and toxicity related to radiation will be summarized by toxicity term and will be presented separately for the on-protocol therapy period and long-term follow-up. |
Up to 5 years
|
|
Swallowing dysfunction
기간: At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using modified Functional Oral Intake Scale (FOIS) and pediatric Eating Assessment Tool (EAT)-10. The EAT-10 consists of 10 items scored from 0 (no impairment) to 4 (severe impairment). Total scores range from 0 to 40; higher scores indicate greater self-perceived impairment. Modified FOIS is an ordinal scale is a rating scale with 7 points for adults and 5 points in pediatrics. It is used to describe the feeding status and patients with dysphagia. Level 1 indicates inability to take anything by mouth while the highest point indicates full oral feeding. Will summarize responses from the modified FOIS and pediatric EAT-10 descriptively for each of these time points. A two-sided Wilcoxon rank-sum test will be performed to test the null hypothesis of equal score between two groups (who receive 54Gy versus 59.4Gy) at the end of the CRIT. Will evaluate the potential impact of other factors, as appropriate, such as baseline scores or disease stages for this analysis. |
At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Quality of life
기간: At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS includes multiple measures such as physical function mobility, anxiety, depressive symptoms, fatigue, etc. PROMIS use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. Higher T-score indicates more of the concept being measured. The numerical T scores of each domain will be summarized descriptively at every time point. |
At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Lymphocyte-to-monocyte ratio (LMR)
기간: At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
Will be assessed the ratio calculated by dividing the absolute lymphocyte count by the absolute monocyte count from a complete blood count with differential analysis performed. Lymphocyte and monocyte counts will be collected at the following time points: baseline, pre-radiation/consolidation, and post-radiation pre-maintenance. Cox proportional hazards regression will be used to evaluate the association between baseline LMR and EFS. The hazard ratio will be reported with a 95% confidence interval. In addition, the LMR will be summarized descriptively by the evaluation time points. |
At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
|
Dental changes
기간: At baseline (prior to radiation) and up to 1 post radiation
|
Will include dental caries and osteoradionecrosis. Dental caries will be quantified as the number of teeth with caries, and bone health will be evaluated as a categorical variable using 0 for no disease and a score of 1-4 to match stage of periodontal disease as described in 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions was co-presented by the American Academy of Periodontology and the European Federation of Periodontology staging framework. Changes over time will be evaluated using paired analyses. Given the small sample size, results will primarily be descriptive, with patient's dental caries and bone health data summarized using descriptive statistics. |
At baseline (prior to radiation) and up to 1 post radiation
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Robyn D Gartrell, Children's Oncology Group
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 악구강 질환
- 부위별 신생물
- 신생물
- 조직학적 유형에 따른 신생물
- 두경부 신생물
- 신생물, 선상 및 상피
- 암종
- 이비인후과 질환
- 인두 신생물
- 이비인후과 신생물
- 비인두 질환
- 인두 질환
- 비인두 신생물
- 비인두암
- 아미노산, 펩티드 및 단백질
- 단백질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 조사 기술
- 치료학
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 수술 절차, 수술
- 세포 학적 기술
- 세포 진단
- 물리적 현상
- 장비 및 용품
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 무기 화학 물질
- 염소 화합물
- 질소 화합물
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 강요
- 궤조
- 진단 기술, 수술
- 화학 기술, 분석
- 스펙트럼 분석
- 금속, 무겁다
- 백금 화합물
- 전자기 현상
- 자기 현상
- 전환 요소
- 전자기 방사선
- 방사선, 이온화
- 니볼루맙
- 젬시타빈
- 시스플라틴
- 1,2-디아미노사이클로헥산백금 II 구연산염
- 방사선 요법
- 방사
- 생검
- 시편 처리
- 자기 공명 분광법
- 백금
- 엑스선
- 팬텀, 이미징
- fluciclovine F-18
기타 연구 ID 번호
- NCI-2023-07208
- U10CA180886 (미국 NIH 보조금/계약)
- NCI-2023-07208 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- ARAR2221 (기타 식별자: CTEP)
- ARAR2221 (기타 식별자: Children's Oncology Group)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .